リック・ドブリン
著作

Frith, C.; Chang, L.; Lattin, D.; Walls, R.; Hamm, J.; Doblin, R. (1987). “Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat”. Fundamental and Applied Toxicology 9 (1):  110–19. doi:10.1016/0272-0590(87)90158-8. http://www.erowid.org/references/refs_view.php?A=ShowDocPartFrame&ID=584&DocPartID=510.
Doblin, R. (1991). “Pahnke's "Good Friday Experiment":  A long-term follow-up and methodological critique”. Journal of Transpersonal Psychology 23 (1):  1–28. http://www.maps.org/research/cluster/psilo-lsd/goodfriday.pdf.
Doblin, R.; Kleiman, M. (May 1, 1991). “Medical use of marijuana”. Annals of Internal Medicine 114 (9):  809–10. doi:10.7326/0003-4819-114-9-809_3. PMID 1842667. http://annals.org/article.aspx?articleid=1077544.
Doblin, R.; Kleiman, M. (July 1991). “Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes.”. Journal of Clinical Oncology 9 (7):  1314–1319. PMID 2045870. http://jco.ascopubs.org/content/9/7/1314.short.
Grinspoon, L.; Bakalar, J.; Doblin, R. (1995). “Marijuana, the AIDS wasting syndrome, and the U.S. government”. The New England Journal of Medicine 333 (10):  670–1. doi:10.1056/nejm199509073331020. PMID 7637743. http://www.nejm.org/doi/full/10.1056/nejm199509073331020.
Doblin, R.; Kleiman, M. (1995). “The medical use of marijuana: the case for clinical trials”. Journal of Addictive Diseases 14 (1):  5–14. doi:10.1300/J069v14n01_02. PMID 7543287.
Doblin, R.; Kleiman, M. (1998). “Survey research vs clinical trials in evaluating the medical utility of marijuana”. Southern Medical Journal 91 (10):  989–91. doi:10.1097/00007611-199810000-00032. PMID 9786301. http://openurl.ebscohost.com/linksvc/linking.aspx?genre=article&sid=PubMed&issn=0038-4348&title=South%20Med%20J&volume=91&issue=10&spage=989&atitle=Survey%20research%20vs%20clinical%20trials%20in%20evaluating%20the%20medical%20utility%20of%20marijuana.&aulast=Doblin&date=1998.
Doblin, R. (1998). “Dr. Leary's Concord Prison Experiment”. Journal of Psychoactive Drugs 30 (4):  419–426. doi:10.1080/02791072.1998.10399715. PMID 9924845. http://www.maps.org/research/1998_Doblin_ConcordPrisonFollow-up.pdf.
Regulation of the Medical Use of Psychedelics and Marijuana . A dissertation by R. Doblin for his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. June 2002.
Doblin, R. (Autumn 2002). “A Clinical Plan for MDMA (Ecstasy) in the Treatment of Post-traumatic Stress Disorder (PTSD): Partnering with the FDA”. MAPS Bulletin 12 (3):  5–18. http://www.maps.org/news-letters/v12n3/12305dob.pdf.
Mithoefer, M.; Jerome, L.; Doblin, R. (2003). “MDMA ('ecstasy') and  neurotoxicity”. Science 300 (5625):  1504–5. doi:10.1126/science.300.5625.1504. PMID 12791964.
Summall, H.; Jerome, L.; Doblin, R. (2004). “Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450”. Psychopharmacology 171 (2):  229–30. doi:10.1007/s00213-003-1599-3. PMID 14634709. http://www.researchgate.net/publication/6730027_The_reality_of_psychomotor_problems_and_the_possibility_of_Parkinson's_disorder_in_some_recreational_ecstasyMDMA_users_a_rejoinder_to_Sumnall_et_al._(2003)/file/d912f50d4c66d8d520.pdf.
Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Doblin, R. (2010). “The safety and efficacy of 3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study”. Journal of Psychopharmacology 25 (4):  439–452. doi:10.1177/0269881110378371. PMC 3122379. PMID 20643699. http://www.maps.org/mdma/ptsdpaper.pdf.
Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Martin, S.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T. et al. (2012). “Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study”. Journal of Psychopharmacology 27 (1):  28–39.. doi:10.1177/0269881112456611. PMC 3573678. PMID 23172889. http://www.maps.org/research/mdma/mithoefer_etal_2012_ltfu.pdf.
Peter, G.; Dominique, H.; Yvonne, M.; R., D.; Berra, Y.-Klosinski; Torsten, P.; Rudolf, B. (2014). “Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases”. The Journal of Nervous and Mental Disease 202 (7):  513–20. doi:10.1097/NMD.0000000000000113. PMID 24594678. http://www.maps.org/research/lsd/Gasser-2014-JMND-4March14.pdf.